Weekly Digest - November 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - November 2024
20 Nov 2024: Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
- NICE has rejected Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu for the third time, failing to reach a reimbursement agreement despite extensive negotiations
- NICE ended talks on November 19, citing that the drug’s pricing was not deemed cost-effective, which led to the refusal to recommend it for use
- The rejection has caused significant disappointment among patients and advocacy groups, as Enhertu is seen as a potentially life-extending treatment for those with HER2-low breast cancer.
- While Enhertu was rejected by NICE, it received approval for NHS use in Scotland and gained European approval, highlighting a discrepancy in access to the drug across regions
